TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
94.18
+1.93 (2.09%)
Apr 24, 2025, 4:00 PM EDT - Market closed
TransMedics Group Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for TransMedics Group stock have an average target of 118.44, with a low estimate of 75 and a high estimate of 178. The average target predicts an increase of 25.76% from the current stock price of 94.18.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for TransMedics Group stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 23, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 26, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $104 | Strong Buy | Maintains | $104 | +10.43% | Mar 11, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 5, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $116 → $75 | Buy → Hold | Downgrades | $116 → $75 | -20.37% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
553.38M
from 441.54M
Increased by 25.33%
Revenue Next Year
666.99M
from 553.38M
Increased by 20.53%
EPS This Year
1.49
from 1.01
Increased by 47.95%
EPS Next Year
2.29
from 1.49
Increased by 53.50%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 583.1M | 720.8M | 858.0M | ||
| Avg | 553.4M | 667.0M | 776.5M | ||
| Low | 526.1M | 612.5M | 693.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.1% | 30.3% | 28.6% | ||
| Avg | 25.3% | 20.5% | 16.4% | ||
| Low | 19.2% | 10.7% | 4.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.89 | 3.14 | 4.20 |
| Avg | 1.49 | 2.29 | 3.02 |
| Low | 1.23 | 1.53 | 2.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 87.1% | 110.1% | 83.1% |
| Avg | 48.0% | 53.5% | 31.7% |
| Low | 22.3% | 2.3% | 3.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.